How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
Claudio U. Köser, Daniela María Cirillo, Paolo Miotto
Abstract
False-susceptible phenotypic drug-susceptibility testing (DST) results for pyrazinamide due to mutations with MICs close to the critical concentration (CC) confound the classification of pncA resistance mutations, leading to an underestimate of the specificity of genotypic DST. This could be minimized by basing treatment decisions on well-understood mutations and by adopting an area of technical uncertainty for phenotypic DST rather than only testing the CC, as is current practice for the Mycobacterium tuberculosis complex.
Topics & Concepts
PyrazinamidePhenotypeGenotypeMycobacterium tuberculosisGeneticsDrug resistanceBiologyDrugMutationTuberculosisComputational biologyMedicinePharmacologyGenePathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisPneumonia and Respiratory Infections